Literature DB >> 17449961

Precursor lesions of pancreatic cancer: molecular pathology and clinical implications.

Mansher Singh1, Anirban Maitra.   

Abstract

BACKGROUND: Pancreatic cancer is a lethal disease, with near uniform 5-year mortality rates. The key to improving survival of pancreatic cancer rests upon early detection of this neoplasm at a resectable, and hence potentially curable, stage.
METHODS: We review the current state of the literature vis-à-vis the three common precursor lesions of pancreatic adenocarcinoma: pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm. We also discuss two clinical scenarios of emerging importance, namely asymptomatic pancreatic cysts ('pancreatic incidentalomas') and the significance of precursor lesions in familial pancreatic cancer kindreds.
RESULTS: Pancreatic intraepithelial neoplasias are the microscopic precursor lesions of pancreatic adenocarcinomas, while intraductal papillary mucinous neoplasms and mucinous cystic neoplasms are macroscopic, cystic precursor lesions. All three noninvasive entities demonstrate a multistep morphologic and genetic progression that culminates in frank invasive adenocarcinoma. Despite these commonalities, each precursor lesion harbors a unique repertoire of clinicopathologic and genetic characteristics that has an impact on natural history and prognosis of these lesions. Due to improvements in radiological techniques, asymptomatic pancreatic cysts are being increasingly discovered in the general population; intraductal papillary mucinous neoplasms and mucinous cystic neoplasms are the most common underlying histology in resected incidentalomas of the pancreas. Pancreatic asymptomatic cysts present an enormous challenge in terms of accurate diagnosis and management stratification. Incorporating molecular signatures of cystic precursor lesions into the diagnostic algorithm will likely become a standard of care for asymptomatic pancreatic cysts. High-risk individuals from familial pancreatic cancer kindreds are another group of individuals where knowledge of precursor lesions has had a therapeutic impact; sensitive imaging technologies have enabled the identification and subsequent resection of pancreatic cancer precursors in these high-risk individuals, preventing the progression to invasive cancer.
CONCLUSIONS: Precursor lesions of pancreatic adenocarcinomas represent a unique opportunity for diagnosis and intervention for a malignancy with near uniform lethality. Further studies on these precursors will enable the development of rational early detection and therapeutic strategies in order to ameliorate pancreatic cancer survival.

Entities:  

Mesh:

Year:  2007        PMID: 17449961     DOI: 10.1159/000101873

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  51 in total

1.  Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer.

Authors:  Sandra Baumgart; Elisabeth Glesel; Garima Singh; Nai-Ming Chen; Kristina Reutlinger; Jinsan Zhang; Daniel D Billadeau; Martin E Fernandez-Zapico; Thomas M Gress; Shiv K Singh; Volker Ellenrieder
Journal:  Gastroenterology       Date:  2011-11-10       Impact factor: 22.682

2.  Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.

Authors:  Brian B Haab; Andrew Porter; Tingting Yue; Lin Li; James Scheiman; Michelle A Anderson; Dawn Barnes; C Max Schmidt; Ziding Feng; Diane M Simeone
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

3.  Mutational spectrum of intraepithelial neoplasia in pancreatic heterotopia.

Authors:  Changqing Ma; Christopher D Gocke; Ralph H Hruban; Deborah A Belchis
Journal:  Hum Pathol       Date:  2015-10-09       Impact factor: 3.466

4.  Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma.

Authors:  Ji Kon Ryu; Hanno Matthaei; Marco Dal Molin; Seung-Mo Hong; Marcia I Canto; Richard D Schulick; Christopher Wolfgang; Michael G Goggins; Ralph H Hruban; Leslie Cope; Anirban Maitra
Journal:  Pancreatology       Date:  2011-07-12       Impact factor: 3.996

Review 5.  Various diffusion magnetic resonance imaging techniques for pancreatic cancer.

Authors:  Meng-Yue Tang; Xiao-Ming Zhang; Tian-Wu Chen; Xiao-Hua Huang
Journal:  World J Radiol       Date:  2015-12-28

6.  N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma.

Authors:  Jessica D Kessler; Hiroshi Hasegawa; Sonja N Brun; Brian A Emmenegger; Zeng-Jie Yang; John W Dutton; Fan Wang; Robert J Wechsler-Reya
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

7.  Widespread and multifocal carcinomas in situ (CISs) through almost the entire pancreas: report of a case with preoperative cytological diagnosis.

Authors:  Makoto Seki; Eiji Ninomiya; Ken Hayashi; Hiroaki Gotoh; Rintaro Koga; Akio Saiura; Keiko Yamada; Masamichi Katori; Yo Kato; Hiroyoshi Okamura
Journal:  Langenbecks Arch Surg       Date:  2009-12-16       Impact factor: 3.445

Review 8.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

9.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

10.  The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target.

Authors:  Aude Legoffic; Ezequiel Calvo; Carla Cano; Emma Folch-Puy; Marc Barthet; Jean Robert Delpero; Montse Ferrés-Masó; Jean Charles Dagorn; Daniel Closa; Juan Iovanna
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.